Cyclacel Pharmaceuticals Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CYCC Nasdaq 2834 http://www.cyclacel.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023 - Jan 5th, 2023 2:15 pm
Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023 - Dec 15th, 2022 2:15 pm
Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update - Nov 9th, 2022 9:05 pm
Here's What to Expect Ahead of Wix's (WIX) Q3 Earnings Release - Nov 7th, 2022 3:33 pm
Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results - Nov 3rd, 2022 1:15 pm
Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022 - Oct 26th, 2022 1:15 pm
Cyclacel Hosting Research & Development Day - Oct 24th, 2022 1:15 pm
Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium - Oct 13th, 2022 1:15 pm
Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference - Sep 21st, 2022 1:15 pm
Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update - Aug 10th, 2022 8:05 pm
Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results - Aug 3rd, 2022 1:15 pm
Cyclacel To Test Higher Doses Of Fadraciclib In Solid Tumor Patients - Jun 30th, 2022 4:46 pm
Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline - Jun 30th, 2022 1:15 pm
Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors - Jun 22nd, 2022 11:04 am
10 Popular Penny Stocks on Robinhood - Jun 14th, 2022 1:23 pm
Cyclacel Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update - May 11th, 2022 8:05 pm
Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results - May 4th, 2022 1:15 pm
Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors and Lymphomas - Apr 19th, 2022 1:15 pm
We're Keeping An Eye On Cyclacel Pharmaceuticals' (NASDAQ:CYCC) Cash Burn Rate - Apr 15th, 2022 12:33 pm
Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia - Apr 12th, 2022 11:00 am